Why the CEO's Portfolio Agenda Must Include New Product Pricing Without Credible Experience
On this page
- Elevating New Product Pricing Risk to the CEOs Strategic Agenda
- Why does the CEO's governance of new products matter more now?
- What goes wrong when the CEO does not include new products on the agenda?
- What do CEOs actually need from the new-product governance?
- Conclusion
- About the author
- Frequently Asked Questions
Elevating New Product Pricing Risk to the CEOs Strategic Agenda
The CEO's portfolio agenda must include new product pricing without credible experience because these products represent the enterprise's riskiest capital allocation—capital deployed against pricing assumptions that are based on judgment rather than data—and the CEO must personally govern the decision to allocate, maintain, increase, or withdraw that capital. The CUO and the CFO manage the new product's underwriting and financial performance, but the CEO owns the strategic decision: is the enterprise's capital being deployed to an innovation that will generate a return, or to an experiment whose assumptions are not being validated by the emerging experience? For CEOs, the new-product agenda item is the governance mechanism that ensures the enterprise's most uncertain capital allocation receives the CEO's direct oversight.
Why does the CEO's governance of new products matter more now?
The CEO's governance matters more now because the reinsurance market is demanding innovation—cyber, parametric, climate-risk products—and the CEO who does not personally govern the innovation risk is delegating the enterprise's riskiest capital decisions to a level below the CEO's visibility. The enterprise risk framework requires the CEO to govern the portfolio's most material risks.
The second reason is the board's expectation that the CEO governs innovation risk: the board will ask the CEO about the new products, their capital allocation, their performance, and the governance framework. A CEO who cannot answer is not governing the portfolio's innovation. The ten forces reshaping reinsurance include innovation governance as a CEO-level capability.
The third reason is the strategic decision that only the CEO can make: whether to continue investing in a new product whose early experience is ambiguous—not clearly validating and not clearly rejecting the pricing assumptions. The CUO and CFO can present the data; the CEO must make the judgment.
What goes wrong when the CEO does not include new products on the agenda?
When the CEO does not include new products: the capital allocation grows without CEO oversight, the governance framework is not defined, the performance monitoring is delegated, the exit decision is delayed, and the CEO discovers the exposure when the losses accumulate.
What do CEOs actually need from the new-product governance?
CEOs need a separate new-product agenda item, defined capital limits, monthly performance data, and a structured decision framework.
Rahul is the CEO of a reinsurer developing cyber products. He added a standing new-product review to his monthly portfolio agenda: the CUO presents the performance, the CFO presents the capital consumed, and Rahul decides whether to maintain, increase, or reduce the allocation. The governance framework gives Rahul direct oversight of the enterprise's riskiest capital.
- A standing new-product agenda item on the CEO's monthly portfolio review.
- A capital-allocation limit for each new product, approved by the CEO.
- Monthly performance data from the CUO and CFO.
- A structured decision framework: maintain, increase, reduce, or exit.
- A board-level new-product report presented by the CEO.
- A direct line of accountability from the CEO to the CUO for new-product governance.
- An annual review of the new-product portfolio strategy by the CEO.
- A communication to the board on the CEO's governance of innovation risk.
Conclusion
For CEOs, new product pricing without credible experience is a governance requirement, and the CEO who includes new products on the portfolio agenda governs the enterprise's riskiest capital allocation directly.
About the author
Hitul Mistry is the Founder of Insurnest, an InsurTech company that engineers end-to-end technology exclusively for the insurance industry serving carriers, TPAs, MGAs, brokers, and reinsurers across India, the UAE, and the US. With more than a decade of insurance domain experience, he has built systems spanning underwriting automation, AI-powered underwriting intelligence, claims management, rating and quoting, broking and agency platforms, and reinsurance automation across Health/GMC, Group Life, Motor, P&C, and Reinsurance. Insurnest doesn't adapt generic software to insurance; it builds from the workflow up.
Connect with Hitul on LinkedIn.
Frequently Asked Questions
Why must the CEO's portfolio agenda include new product pricing?
Because new products without credible experience represent the enterprise's riskiest capital allocation, and the CEO must personally govern the decision to allocate capital to an unproven pricing assumption.
What is the CEO's role in new product pricing governance?
The CEO must approve the capital allocation to the new product, set the governance framework, review the performance at the defined intervals, and decide whether to maintain, increase, or withdraw the allocation.
How does the CEO govern the new-product risk alongside the rest of the portfolio?
By treating the new product as a separate governance item on the portfolio agenda, with its own limits, monitoring, and exit criteria, distinct from the established lines.
What question should the CEO ask the CUO and CFO about new products?
What is the maximum capital at risk, what are the conditions under which we will withdraw, and how frequently are we monitoring the emerging experience?
How does the CEO's governance of new products affect the enterprise's innovation culture?
By governing the risk, the CEO creates the space for innovation—the underwriting team knows the boundaries, the capital is protected, and the innovation can proceed within a governed framework.
What is the consequence of the CEO not including new products on the agenda?
The new product grows without CEO-level governance, the capital allocation expands beyond the enterprise's tolerance, and the CEO discovers the exposure when the loss experience deteriorates.
How should the CEO present the new-product governance to the board?
As a separate agenda item: the new-product portfolio, the capital allocated, the performance to date, the governance framework, and the CEO's assessment.
What is the strategic decision the CEO must make?
Whether the new product's emerging experience supports continued investment, and whether the pricing assumptions are being validated or rejected by the data.
Hitul Mistry
CEO, Insurnest
An InsurTech leader with more than a decade of experience across insurance and technology, focused on solving business problems with the help of technology. Has worked with brokers, insurance carriers, and reinsurance firms across the India, UAE, and US markets.
View LinkedIn profile →
